Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's Antimicrobial Head Ed Cox Leaves For Regeneron; Agency Needs New LPAD Champion

Aug 27 2019

• By Michael Cipriano

FDAEntrance_1200x675

Related Content

Antibiotic Stakeholders Discuss Ethics Of Testing Limited Population Drugs In Broader Populations

Jul 18 2019

Can Real-World Evidence Be Used To Remove LPAD's Limited Population Designation?

Jul 10 2019

LPAD As An Afterthought? Insmed’s Arikayce Reaches US Market Thanks To Limited Population Pathway

Oct 03 2018

Lauren Silvis To Depart US FDA, Adding To High-Level String Of Agency Turnover In 2019

Jun 03 2019

Antibiotic Test Case: Will LPAD + Non-Inferiority = Approval For Plazominicin's BSI Indication?

May 17 2018

Antibacterial Development: Industry Cautious About Role Of Animal Models

Mar 09 2017

Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out

Jun 27 2018

LPAD Approval Pathway Is Not Saving Antimicrobial Development

Nov 28 2018

Antibiotic Guidance: Limited Populations Do Not Include Rare Infections

Jun 12 2018

Related Companies

Regeneron Pharmaceuticals, Inc.

Achaogen, Inc.

CorMedix Inc.

Global Alliance for TB Drug Development

Insmed Incorporated

Mapp Biopharmaceutical

Gilead Sciences, Inc.

F2G Ltd

AstraZeneca PLC

Additional Topics

United States FDA Leadership Regulation Infectious Diseases BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window